Trusted CBD Sources

The list of medicines licensed in Turkey. The October 16, 2026 list contains no medicine containing CBD.

Ways to report a side effect in Turkey: online form, toll-free phone (0 800 314 00 08) or email.

An official document that explains, step by step, how to report a side effect and what information to include (PDF).

The types of cannabis products in Turkey, including CBD, their licensing, sale in pharmacies and tracking.

The status of CBD as a drug, a food and a supplement; frequently asked questions, including on pregnancy and pets.

Warnings sent about CBD products sold with claims to treat diseases, and some product test results.

An official warning against CBD and cannabis products during pregnancy and breastfeeding.

The official prescribing information for the approved CBD medicine: approved uses, side effects, liver monitoring and interactions.

The European assessment report and product information for the approved CBD medicine.

The provisional safe daily level in adults for CBD sold as food (about 2 mg for a 70 kg adult).

The recommended daily upper limit of food CBD for healthy adults, and the groups who should not use it.

A public, searchable list of CBD products going through the authorization process for sale in the UK.

The difference between approved medicines and CBD sold in shops, who can be prescribed it, and the risks.

The expert committee's assessment of CBD's safety and risk of dependence (PDF).

Prohibited substances for athletes. CBD is not banned; THC and similar substances are banned in competition (PDF, 2027 list).

A monograph on cannabis and cannabinoids for doctors.

Guidance documents for doctors and evidence summaries by condition.

The UK's health technology appraisal: approved CBD, together with clobazam, in patients aged 2 and over; drop seizures are reviewed every 6 months, and the medicine is stopped if there is not at least a 30% reduction.

Canada's drug assessment agency's reimbursement recommendation for approved CBD as an add-on treatment in patients aged 2 and over with Lennox–Gastaut syndrome.

The UK's health technology appraisal: approved CBD, together with clobazam, in patients aged 2 and over; convulsive seizures are reviewed every 6 months, and the medicine is stopped if there is not at least a 30% reduction.

For approved CBD in severe treatment-resistant epilepsy, the UK guideline refers only to the appraisals for tuberous sclerosis, Lennox–Gastaut and Dravet syndrome; it lists the effectiveness of CBD in the epilepsies, and the effect of adding THC to CBD, as questions that need research.

This guideline from the US veterans and defense departments makes a strong recommendation against cannabis and cannabis-derived products for the treatment of PTSD (very low confidence in the evidence).

A 2023 rapid review by Canada's drug assessment agency on nabilone, a synthetic THC-like medicine, for the treatment of PTSD (an update of its earlier reports).

An evidence summary condition by condition, plus safety information.

Summary information, links to clinical trials and articles, and patient handouts.

A plain-language summary of an independent systematic review: benefits and risks, and the certainty of the evidence.

CBD clinical trials registered worldwide, both those recruiting patients and those with results.

A database of CBD research published in peer-reviewed journals. The PMID numbers on our site link here.

Data on the passage of cannabis and CBD into breast milk.

An up-to-date evidence report on the medical use of cannabis and cannabinoids (PDF).

The European Glaucoma Society's guideline states that there is no evidence supporting a role for cannabinoids in the treatment of glaucoma (low level of evidence, strong recommendation).

The Society writes that marijuana lowers eye pressure for only 3–4 hours, and that because of its side effects, short duration of action and the lack of evidence that it changes the course of the disease, it cannot currently be recommended in any form for treating glaucoma. The 2019 pediatric glaucoma statement on the same page also does not support the use of cannabinoids in childhood glaucoma.

A two-round consensus by an international panel of physicians and caregivers. Caregivers strongly supported using pharmaceutical-grade CBD as a first or second option, while physicians did not reach consensus on this; physicians did strongly agree on using it as a first, second or third option. Physicians strongly agreed that CBD products that are not pharmaceutical grade should not be recommended, while caregivers did not reach consensus (this is expert opinion).

The English text of this guideline, published in the journal, recommends psychotherapy and certain antidepressants as first-line treatment for anxiety disorders and does not mention cannabinoids at all.

The full text of this guideline, which recommends antidepressants, benzodiazepines and pregabalin for drug treatment and individual cognitive behavioral therapy for psychotherapy, does not mention cannabinoids at all.

A free tool that shows how THC and CBD may affect the breakdown of other medicines in the body; results can be printed.

Interactions between CBD and hundreds of medicines, by severity (major, moderate, minor).

The difference between the approved CBD medicine and unregulated CBD products; interactions with clobazam and valproate.

A short expert answer, with sources.

A physician-written summary that presents the evidence impartially.

CBD's possible benefits and risks, with expert opinion.

A summary of research by condition, plus safety information. Some details are paid.

CBD's effects, risks, and information on pregnancy and breastfeeding, in plain language.

Lab testing of the amount of CBD and THC in CBD products on the market. Most results are available to members only (paid).

The Academy does not recommend marijuana or other cannabis products for treating glaucoma until more research is done. It explains that because eye pressure must be kept under control 24 hours a day, cannabis products, including CBD, are not a practical treatment, and that there is no convincing research showing CBD is effective in glaucoma.